In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility

Aims:  This study compared the in vitro activity of telithromycin with that of azithromycin against 438 Streptococcus pyogenes and 198 Streptococcus pneumoniae, isolated over the period 2005–2007 from specimens of different human origin obtained in three Piemonte Region’s hospitals.

[1]  M. Kaku,et al.  Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004). , 2008, Microbial drug resistance.

[2]  R. Koncan,et al.  Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to Macrolides and Telithromycin: Data from an Italian Multicenter Study , 2007, Journal of chemotherapy.

[3]  T. Kaneko,et al.  Novel tethers in ketolide antibiotics. , 2007, Bioorganic & medicinal chemistry letters.

[4]  R. Cantón,et al.  Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. , 2007, The Journal of infection.

[5]  R. Koncan,et al.  Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. , 2007, The Journal of antimicrobial chemotherapy.

[6]  T. File,et al.  Prevalence and Antibacterial Susceptibility of mef(A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US Study , 2006, Journal of Clinical Microbiology.

[7]  L. Drago,et al.  Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  A. Shibl,et al.  Patterns of Macrolide Resistance Determinants among S. pyogenes and S. pneumoniae Isolates in Saudi Arabia , 2005, The Journal of international medical research.

[9]  F. Gallé,et al.  T Serotyping and Genomic Profile of Erythromycin- Resistant or -Sensitive Streptococcus pyogenes Isolated in Campania Region, Italy , 2005, Journal of chemotherapy.

[10]  K. Ramotar,et al.  Prevalence and Mechanisms of Erythromycin Resistance in Group A and Group B Streptococcus: Implications for Reporting Susceptibility Results , 2004, Journal of Clinical Microbiology.

[11]  Steven D. Brown,et al.  Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. , 2004, The Journal of antimicrobial chemotherapy.

[12]  D. Farrell,et al.  Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators. , 2004, The Journal of infection.

[13]  Steven D. Brown,et al.  Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001 , 2003, Southern medical journal.

[14]  A. Vatopoulos,et al.  In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  J. Garau,et al.  Importance of dose and duration of beta-lactam therapy in nasopharyngeal colonization with resistant pneumococci. , 2002, The Journal of antimicrobial chemotherapy.

[16]  I. Morrissey,et al.  Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. , 2002, The Journal of antimicrobial chemotherapy.

[17]  F. Baquero,et al.  Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. , 2002, The Journal of antimicrobial chemotherapy.

[18]  R. Leclercq,et al.  Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. , 2002, The Journal of antimicrobial chemotherapy.

[19]  R. Leclercq,et al.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. P. Montanari,et al.  Differentiation of Resistance Phenotypes among Erythromycin-Resistant Pneumococci , 2001, Journal of Clinical Microbiology.

[21]  P. Huovinen,et al.  In Vitro Activities of the Novel Ketolide Telithromycin (HMR 3647) against Erythromycin-Resistant StreptococcusSpecies , 2001, Antimicrobial Agents and Chemotherapy.

[22]  M. P. Montanari,et al.  In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. , 2000, The Journal of antimicrobial chemotherapy.

[23]  A. Marchese,et al.  Resistance patterns of lower respiratory tract pathogens in Europe. , 2000, International journal of antimicrobial agents.

[24]  H. Goossens,et al.  Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. , 2000, The Journal of antimicrobial chemotherapy.

[25]  M. P. Montanari,et al.  Phenotypes and Genotypes of Erythromycin-ResistantStreptococcus pyogenes Strains in Italy and Heterogeneity of Inducibly Resistant Strains , 1999, Antimicrobial Agents and Chemotherapy.

[26]  M. Kaku,et al.  Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1–3 (1999–2002) , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[27]  S. Douthwaite,et al.  The ketolides: a critical review. , 2002, Drugs.

[28]  D. Figgitt,et al.  Telithromycin. Author's Reply , 2001 .

[29]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[30]  M. Zucca,et al.  Macrolide resistance in group A streptococci. , 2000, The Journal of antimicrobial chemotherapy.

[31]  Steven D. Brown,et al.  Annals of Clinical Microbiology and Antimicrobials Open Access Trends in Antibacterial Resistance among Streptococcus Pneumoniae Isolated in the Usa: Update from Protekt Us Years 1–4 , 2022 .